FOUNDAYO (orforglipron) approved as the first small molecule oral GLP-1 therapy for weight loss скачать в хорошем качестве

FOUNDAYO (orforglipron) approved as the first small molecule oral GLP-1 therapy for weight loss

This video provides a concise summary for FOUNDAYO (orforglipron), a newly FDA-approved once-daily oral GLP-1 therapy for weight loss, offering an attractive treatment approach to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight. ⏱️ Timestamps 00:00 Overview 01:20 Indication and use 01:56 Drug chemistry 02:51 Dosage forms and recommended dosage 04:43 How this medication works 05:00 Pharmacokinetics 06:06 Drug-drug interactions and contraindications 08:07 Adverse effects 08:34 References 📚 References FDA Novel Drug Approvals for 2026 (https://www.fda.gov/drugs/novel-drug-.... FOUNDAYO (orforglipron) [prescribing information]. Indianapolis, IN: Lilly USA, LLC; April 2026. https://pi.lilly.com/us/foundayo-uspi... (accessed: April 5, 2026). #newdrugapprovals #FOUNDAYO #orforglipron #pharmanews #WeightLoss #FDAApproval #NewDrugs #Pharmacology #DrugUpdate #MedicalEducation #PharmacyEducation Keywords: FOUNDAYO, Orforglipron, Orforglipron FDA approval, Oral GLP-1 receptor agonist, GLP-1 drugs 2026, Weight loss GLP-1 oral, Pharmacology GLP-1, FDA new drug approval, FOUNDAYO pharmacokinetics, FOUNDAYO side effects, FDA new drug 2026, pharmacy education 💊 Subscribe for more weekly videos on new drug approvals and medication insights. Disclaimer: The Medication Academy YouTube channel is for educational purposes only and is not intended to provide diagnosis, treatment, or medical advice. In addition, the creator of this channel has no financial interests to disclose with pharmaceutical companies and is not affiliated with the US FDA.